NEWS
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Published On :
(Reuters) – Novo Nordisk’s chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.
(Reporting by Disha Mishra in Bengaluru; Editing by Christopher Cushing)
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.
-
-
BUSINESS3 days ago
UK pay growth weakest since February 2021, REC survey show
-
-
-
NEWS3 days ago
Japan leads Asia stock rally, dollar firms after blowout US payrolls
-
-
-
NEWS3 days ago
Adani Group in talks to buy Heidelberg’s Indian cement operations, paper says
-
-
-
INVESTING3 days ago
Manchester-based mobile network sees unprecedented growth and attracts major investment.
-